Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies

NCT02376699 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02376699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02376699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2015
Completion date
April 14, 2023
Enrollment
159 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, squamous cell, hodgkin disease, lymphoma, lymphoma, b-cell, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, melanoma, neoplasm metastasis, neoplasms, head and neck, neoplasms, squamous cell, non-small cell carcinoma, non-small cell lung cancer, non-small cell lung cancer metastatic, pancreatic adenocarcinoma, squamous cell cancer, squamous cell carcinoma, squamous cell carcinoma of the head and neck, squamous cell neoplasm